Clinical Trial Update: Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. [Phase 4]

View source ↗

Summary

A Phase 4 window-of-opportunity pilot trial evaluating methylnatrexone in resectable head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Methylnatrexone (methylnatrexone)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 4 | Status: RECRUITING